|1.||Strebhardt, Klaus: 14 articles (12/2015 - 08/2002)|
|2.||Ahmad, Nihal: 11 articles (12/2015 - 04/2005)|
|3.||Liu, Xiaoqi: 11 articles (12/2015 - 09/2003)|
|4.||Yuan, Juping: 8 articles (10/2015 - 08/2002)|
|5.||Kaufmann, Manfred: 8 articles (08/2010 - 08/2002)|
|6.||Spänkuch, Birgit: 7 articles (03/2011 - 06/2004)|
|7.||Schmidt, Mathias: 6 articles (12/2007 - 08/2004)|
|8.||Munzert, Gerd: 5 articles (06/2015 - 12/2008)|
|9.||Zimmer, Brigitte: 5 articles (03/2015 - 06/2004)|
|10.||Liu, Lin: 5 articles (01/2015 - 04/2006)|
11/01/2013 - "Current clinical trials with polo-like kinase 1 inhibitors in solid tumors."
11/01/2011 - "Polo-like kinase 1 (PLK1) is a key regulator of mitotic progression and cell division, and small molecule inhibitors of PLK1 are undergoing clinical trials to evaluate their utility in cancer therapy. "
12/01/2015 - "Polo-like kinase 1 (PLK1) is frequently overexpressed in cancer, which correlates with poor prognosis. "
12/01/2015 - "The expression of polo-like kinase 1 (Plk1) correlates with malignancy and is thus recognized as a target for cancer therapy. "
03/30/2015 - "By contrast, deficiency of p21 renders tumor cells more susceptible to Polo-like kinase 1 inhibition by showing a pronounced mitotic arrest, DNA damage and apoptosis. "
08/01/1995 - "The nucleotide sequence of the entire coding regions shows that this clone, designated Plk1(polo like kinase 1), is identical with STPK13 previously cloned from murine erythro-leukemia cells. "
08/01/2012 - "At present, the number of clinical trials that are registered with the European Organization for Research and Treatment of Cancer (EORTC) and with the US National Cancer Institute, which investigate the efficacy of Polo-like kinase 1 (Plk1) inhibitors against solid tumors and different types of leukemia is growing. "
01/01/2015 - "We found that the PLK1 protein was highly expressed in leukemia cell lines as well as 73.3% (11/15) of pediatric acute myeloid leukemia (AML) samples. "
02/20/2003 - "Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)."
01/15/2013 - "To determine whether Polo-like kinase 1 (PLK1) inhibitors (e.g., BI2536) and histone deacetylase (HDAC) inhibitors (e.g., vorinostat) interact synergistically in the BCR/ABL(+) leukemia cells sensitive or resistant to imatinib mesylate (IM) in vitro and in vivo. "
|3.||Hematologic Neoplasms (Hematological Malignancy)
09/01/2009 - "A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies."
04/01/2015 - "Polo-like kinase 1 (PLK1) is an important regulator of the cell cycle and is overexpressed in various solid and hematological malignancies. "
04/01/2012 - "NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies."
10/01/2013 - "This study investigated Polo-like kinase 1, a mitotic regulator often over-expressed in solid tumors and adult hematopoietic malignancies, as a potential new target in the treatment of pediatric acute lymphoblastic leukemia. "
|4.||Sarcoma (Soft Tissue Sarcoma)
10/02/2015 - "In order to develop novel targeted therapies, we tested the efficacy of polo-like kinase 1 (PLK-1) inhibitor (TAK-960) in sarcoma. "
10/02/2015 - "Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression."
08/01/2010 - "Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. "
|5.||Neoplasm Metastasis (Metastasis)
10/01/2013 - "To investigate whether Plk1 plays a general role in bladder urothelial carcinoma, we examined the expression of Plk1 protein in bladder urothelial carcinoma and cell lines, and analyzed the relationship among Plk1 protein expression, metastasis, and recurrence of urinary bladder urothelial carcinoma. "
10/01/2013 - "High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder."
07/01/2013 - "In this regard, restoration of p53 in tumor cells with loss or mutation of p53 will reinforce the cytotoxicity of combined Polo-like kinase 1 therapy and provide a proficient strategy for combating relapse and metastasis of cancer. "
09/01/2011 - "By gene set enrichment analysis, we identified the cell-cycle pathway and its member polo-like kinase 1 (Plk-1) to be significantly overexpressed in primary melanomas and in melanoma metastases. "
01/01/2012 - "High polo-like kinase 1 expression was significantly correlated with advanced clinical stage, higher tumor classification and lymph node metastasis of non-small cell lung cancer patients (P=0.001, 0.004 and 0.001, respectively). "
|2.||Proteins (Proteins, Gene)
|4.||GTP Phosphohydrolases (GTPases)
|6.||Small Interfering RNA (siRNA)
|7.||Protein-Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)
|8.||Messenger RNA (mRNA)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Drug Therapy (Chemotherapy)